What is Atyr Pharma Inc's earnings per share (EPS)?

Atyr Pharma Inc (ATYR) reported diluted earnings per share of -$0.80 for fiscal year 2025. This represents a 7.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atyr Pharma Inc Financials

ATYR

FY2025 annual

Revenue $190K -19.1% YoY

Net Income -$74.1M -15.8% YoY

EPS (Diluted) -$0.80 +7.0% YoY

Free Cash Flow -$62.1M +10.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Atyr Pharma Inc (ATYR) reported $190K in revenue for fiscal year 2025, down 19.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATYR FY2025 2026-08-15

A development-stage model is consuming capital faster than revenue can fund operations, making external financing the central business mechanic.

In FY2025, R&D spending reached $60.2M against revenue of $190K, keeping the model research-led rather than sales-funded. Operating cash flow of -$62.0M tracked net income of -$74.1M, so losses were largely cash costs rather than merely accounting charges; the cash-conversion gap is limited.

The commercial base has not caught up with investment: R&D intensity was more than 300x revenue in FY2025, keeping the company research-led rather than sales-funded. Revenue fell from $353K in FY2023 to $190K in FY2025, so recent spending cannot be interpreted as fixed-cost absorption from expanding volume.

The balance sheet looks liquid on a ratio basis, with current assets exceeding current liabilities, but cash was only $10.7M against annual operating cash flow of -$62.0M. Financing cash flow of $66.0M substantially offset operations, showing that liquidity has depended on external funding rather than internally generated cash.

Financial Health Signals

Financial health score not available

Atyr Pharma Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-9.79

Atyr Pharma Inc scores -9.79, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($53.0M) relative to total liabilities ($25.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Atyr Pharma Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Atyr Pharma Inc reported a net loss of $74.1M while operations used $62.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$190K

YoY-19.1%

5Y CAGR-55.1%

Atyr Pharma Inc generated $190K in revenue in fiscal year 2025. This represents a decrease of 19.1% from the prior year.

EBITDA

-$77.0M

YoY-14.5%

Atyr Pharma Inc's EBITDA was -$77.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the prior year.

Net Income

-$74.1M

YoY-15.8%

Atyr Pharma Inc reported -$74.1M in net income in fiscal year 2025. This represents a decrease of 15.8% from the prior year.

EPS (Diluted)

-$0.80

YoY+7.0%

Atyr Pharma Inc earned -$0.80 per diluted share (EPS) in fiscal year 2025. This represents an increase of 7.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$62.1M

YoY+10.3%

Atyr Pharma Inc recorded an outflow of $62.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 10.3% from the prior year.

Cash & Debt

$10.7M

YoY-2.8%

5Y CAGR-8.7%

10Y CAGR-14.8%

Atyr Pharma Inc held $10.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

98M

YoY+10.3%

Atyr Pharma Inc had 98M shares outstanding in fiscal year 2025. This represents an increase of 10.3% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-109.8%

YoY-18.4pp

5Y CAGR-58.6pp

10Y CAGR-68.1pp

Atyr Pharma Inc's ROE was -109.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$60.2M

YoY+10.8%

5Y CAGR+28.3%

10Y CAGR+5.7%

Atyr Pharma Inc invested $60.2M in research and development in fiscal year 2025. This represents an increase of 10.8% from the prior year.

Capital Expenditures

$77K

YoY+18.5%

5Y CAGR-17.5%

10Y CAGR-19.4%

Atyr Pharma Inc invested $77K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 18.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

ATYR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATYR quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	N/A	$190K-19.1%	$235K-33.4%	$353K-96.6%	$10.4M	$0-100.0%	$10.5M+2377.5%	$422K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$60.2M+10.8%	$54.4M+28.6%	$42.3M-1.2%	$42.8M+84.0%	$23.3M+34.5%	$17.3M+23.1%	$14.0M-31.1%	$20.4M-32.2%	$30.1M-29.8%	$42.8M+24.2%	$34.5M+105.7%	$16.8M+21.3%	$13.8M
SG&A Expenses	N/A	$17.6M+27.7%	$13.8M+6.1%	$13.0M-7.2%	$14.0M+30.1%	$10.8M+18.5%	$9.1M-3.0%	$9.4M-24.8%	$12.4M-27.2%	$17.1M+13.1%	$15.1M+15.1%	$13.1M+93.5%	$6.8M+18.7%	$5.7M
Operating Income	N/A	-$77.6M-14.3%	-$67.9M-23.7%	-$54.9M-18.3%	-$46.4M-36.4%	-$34.0M-113.8%	-$15.9M+30.8%	-$23.0M+30.0%	-$32.8M+30.4%	-$47.1M+18.6%	-$57.9M-21.7%	-$47.6M-102.2%	-$23.6M-20.5%	-$19.5M
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	N/A	-$49K	N/A	N/A	N/A
Net Income	N/A	-$74.1M-15.8%	-$64.0M-27.1%	-$50.4M-11.1%	-$45.3M-34.3%	-$33.8M-108.1%	-$16.2M0.0%	-$16.2M+53.0%	-$34.5M+28.4%	-$48.2M+16.7%	-$57.9M-20.6%	-$48.0M-97.0%	-$24.4M-21.7%	-$20.0M
EPS (Diluted)	-$0.62	-$0.80+7.0%	-$0.86+8.5%	-$0.94	-$1.60	-$1.77	-$1.77	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	$190K	$0	$0	N/A	$0
R&D Expenses	$6.7M-7.8%	$7.3M	N/A	$22.1M+43.9%	$15.4M+30.2%	$11.8M	N/A	$14.8M
SG&A Expenses	$4.1M+0.3%	$4.1M	N/A	$4.8M-2.5%	$4.9M+24.5%	$4.0M	N/A	$3.3M
Operating Income	-$10.9M+4.9%	-$11.4M	N/A	-$26.7M-31.7%	-$20.3M-28.8%	-$15.8M	N/A	-$18.1M
Net Income	-$10.3M+4.5%	-$10.8M	N/A	-$25.7M-31.8%	-$19.5M-31.3%	-$14.9M	N/A	-$17.3M
EPS (Diluted)	-$0.110.0%	-$0.11+21.4%	-$0.14+46.2%	-$0.26-18.2%	-$0.22-29.4%	-$0.170.0%	-$0.17+26.1%	-$0.23

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

ATYR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATYR quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$93.0M-4.0%	$96.8M-19.7%	$120.7M+26.0%	$95.8M-17.1%	$115.5M+198.3%	$38.7M+7.0%	$36.2M-31.4%	$52.7M-41.0%	$89.4M+11.0%	$80.5M-37.9%	$129.7M+528.1%	$20.6M	N/A
Current Assets	$80.2M-2.1%	$82.0M-20.4%	$103.0M+27.4%	$80.9M-28.8%	$113.6M+219.6%	$35.5M+11.3%	$31.9M-37.2%	$50.8M-41.6%	$87.0M+16.3%	$74.8M-23.7%	$98.0M+493.3%	$16.5M	N/A
Cash & Equivalents	$10.7M-2.8%	$11.1M-51.0%	$22.5M+125.9%	$10.0M+327.3%	$2.3M-86.2%	$17.0M+84.1%	$9.2M-59.9%	$23.0M+8.9%	$21.1M-45.1%	$38.4M-27.6%	$53.0M+281.5%	$13.9M-61.9%	$36.5M
Total Liabilities	$25.5M-4.8%	$26.8M-10.6%	$30.0M+23.3%	$24.3M+290.0%	$6.2M-11.9%	$7.1M-52.8%	$15.0M-21.4%	$19.1M-24.0%	$25.1M+41.7%	$17.7M+21.2%	$14.6M-86.9%	$111.7M	N/A
Current Liabilities	$15.1M+1.2%	$15.0M-8.8%	$16.4M+18.4%	$13.9M+130.5%	$6.0M+2.5%	$5.9M-54.6%	$12.9M+19.3%	$10.8M+4.3%	$10.4M+21.9%	$8.5M-29.8%	$12.1M+20.1%	$10.1M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$8.3M-43.9%	$14.7M+60.0%	$9.2M+417.9%	$1.8M	N/A	N/A
Total Equity	$67.5M-3.6%	$70.0M-22.8%	$90.7M+26.9%	$71.5M-34.6%	$109.3M+245.3%	$31.6M+49.4%	$21.2M-37.0%	$33.6M-47.6%	$64.2M+2.3%	$62.8M-45.4%	$115.0M+226.4%	-$91.0M-37.7%	-$66.1M
Retained Earnings	-$606.2M-13.9%	-$532.0M-13.7%	-$468.0M-12.1%	-$417.6M-12.2%	-$372.3M-10.0%	-$338.5M-5.0%	-$322.3M-7.9%	-$298.7M-13.1%	-$264.2M-22.3%	-$216.0M-36.6%	-$158.1M-43.6%	-$110.2M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$69.8M-12.3%	$79.7M-14.4%	$93.0M-12.8%	$106.7M+5.0%	$101.5M+4.4%	$97.2M+0.4%	$96.8M+5.7%	$91.6M
Current Assets	$58.4M-13.6%	$67.6M-15.8%	$80.2M-13.7%	$93.0M+6.3%	$87.5M+5.1%	$83.3M+1.6%	$82.0M+7.4%	$76.3M
Cash & Equivalents	$16.2M+61.5%	$10.0M-6.8%	$10.7M+74.7%	$6.2M-64.3%	$17.2M+66.2%	$10.4M-6.3%	$11.1M-3.5%	$11.5M
Total Liabilities	$21.0M-3.1%	$21.7M-14.9%	$25.5M-3.4%	$26.4M-1.0%	$26.7M+20.2%	$22.2M-17.2%	$26.8M+2.0%	$26.3M
Current Liabilities	$11.4M-2.6%	$11.7M-22.8%	$15.1M-3.4%	$15.7M+0.9%	$15.5M+45.4%	$10.7M-28.6%	$15.0M+6.0%	$14.1M
Total Equity	$48.8M-15.8%	$57.9M-14.1%	$67.5M-15.9%	$80.2M+7.2%	$74.8M-0.3%	$75.0M+7.2%	$70.0M+7.2%	$65.3M
Retained Earnings	-$627.3M-1.7%	-$617.0M-1.8%	-$606.2M-2.4%	-$592.2M-4.5%	-$566.5M-3.6%	-$546.9M-2.8%	-$532.0M-2.9%	-$517.1M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ATYR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATYR quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$54.5M	-$62.0M+10.3%	-$69.1M-108.1%	-$33.2M+20.7%	-$41.9M-26.6%	-$33.1M-116.2%	-$15.3M+23.5%	-$20.0M+35.6%	-$31.1M+26.7%	-$42.4M+19.9%	-$52.9M-43.7%	-$36.8M-61.2%	-$22.8M-31.8%	-$17.3M
Capital Expenditures	$279K	$77K+18.5%	$65K-98.5%	$4.2M+156.9%	$1.6M+754.7%	$192K-5.0%	$202K+155.7%	$79K-86.7%	$594K-54.7%	$1.3M+118.7%	$600K-9.6%	$664K+166.7%	$249K-61.3%	$644K
Free Cash Flow	-$54.8M	-$62.1M+10.3%	-$69.2M-84.8%	-$37.4M+14.0%	-$43.5M-30.8%	-$33.3M-114.6%	-$15.5M+22.8%	-$20.1M+36.5%	-$31.7M+27.5%	-$43.7M+18.3%	-$53.5M-42.7%	-$37.5M-62.4%	-$23.1M-28.5%	-$18.0M
Investing Cash Flow	$22.9M	-$5.1M-129.3%	$17.2M+185.6%	-$20.1M-142.6%	$47.2M+151.6%	-$91.6M-1427.0%	$6.9M+40.1%	$4.9M-86.8%	$37.2M+234.5%	-$27.6M-182.4%	$33.5M	N/A	N/A	N/A
Financing Cash Flow	$29.2M	$66.0M+65.6%	$39.9M-39.8%	$66.2M+1115.0%	$5.5M-95.0%	$110.0M+581.6%	$16.1M+1108.3%	$1.3M+131.5%	-$4.2M-108.0%	$52.7M+1022.1%	$4.7M	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$9.4M+25.3%	-$12.5M-2.6%	-$12.2M+40.4%	-$20.5M-47.4%	-$13.9M+9.9%	-$15.4M-17.4%	-$13.1M+0.2%	-$13.2M
Capital Expenditures	$73K-47.1%	$138K+345.2%	$31K-16.2%	$37K+311.1%	$9K	$0-100.0%	$25K+66.7%	$15K
Free Cash Flow	-$9.4M+25.5%	-$12.7M-3.5%	-$12.2M+40.4%	-$20.5M-47.5%	-$13.9M+9.8%	-$15.4M-17.2%	-$13.2M+0.1%	-$13.2M
Investing Cash Flow	$15.3M+33.3%	$11.5M-30.1%	$16.4M+180.7%	-$20.4M-717.3%	$3.3M+174.7%	-$4.4M+27.4%	-$6.1M-133.9%	$17.9M
Financing Cash Flow	-$129K+9.2%	-$142K-8.4%	-$131K-100.4%	$29.6M+65.5%	$17.9M-3.9%	$18.6M-1.1%	$18.8M+18041.9%	-$105K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATYR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

ATYR quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Margin	-40856.3%	-28899.6%	-15557.8%	-446.8%	N/A	-152.2%	-5445.0%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-39009.5%	-27243.8%	-14274.5%	-436.5%	N/A	-155.2%	-3844.6%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-109.8%-18.4pp	-91.4%-35.9pp	-55.6%+7.9pp	-63.4%-32.5pp	-30.9%+20.4pp	-51.3%+25.3pp	-76.6%+26.0pp	-102.6%-27.5pp	-75.0%+17.1pp	-92.1%-50.4pp	-41.7%	N/A	N/A
Return on Assets	-79.7%-13.6pp	-66.1%-24.4pp	-41.8%+5.6pp	-47.3%-18.1pp	-29.2%+12.7pp	-41.9%+2.9pp	-44.8%+20.6pp	-65.4%-11.5pp	-53.9%+17.9pp	-71.9%-34.9pp	-37.0%+81.0pp	-118.0%	N/A
Current Ratio	5.30-0.2x	5.48-0.8x	6.27+0.4x	5.83-13.1x	18.89+12.8x	6.06+3.6x	2.47-2.2x	4.69-3.7x	8.37-0.4x	8.77+0.7x	8.06+6.4x	1.63	N/A
Debt-to-Equity	0.380.0x	0.38+0.1x	0.330.0x	0.34+0.3x	0.06-0.2x	0.22-0.5x	0.71+0.5x	0.250.0x	0.23+0.1x	0.15+0.1x	0.02	N/A	N/A
FCF Margin	-32664.7%	-29440.0%	-10605.1%	-419.1%	N/A	-148.3%	-4761.1%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	N/A	N/A	N/A	-14076.3%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-13549.5%	N/A	N/A	N/A	N/A
Return on Equity	-21.1%-2.5pp	-18.6%	N/A	-32.1%-6.0pp	-26.1%-6.3pp	-19.8%	N/A	-26.4%
Return on Assets	-14.8%-1.2pp	-13.6%	N/A	-24.1%-4.9pp	-19.2%-3.9pp	-15.3%	N/A	-18.8%
Current Ratio	5.12-0.7x	5.78+0.5x	5.30-0.6x	5.93+0.3x	5.63-2.2x	7.79+2.3x	5.48+0.1x	5.41
Debt-to-Equity	0.43+0.1x	0.370.0x	0.380.0x	0.330.0x	0.36+0.1x	0.30-0.1x	0.380.0x	0.40
FCF Margin	N/A	N/A	N/A	-10796.3%	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Sage Therapeutic SAGE

$543.6M

Opthea Ltd OPT

$524.8M

Kodiak Sciences Inc. KOD

$2.5B

Oruka Therapeutics Inc ORKA

$6.4B

Olema Pharmaceuticals, Inc. OLMA

$944.1M

Where Atyr Pharma Inc Ranks

Frequently Asked Questions

What is Atyr Pharma Inc's annual revenue?

Atyr Pharma Inc (ATYR) reported $190K in total revenue for fiscal year 2025. This represents a -19.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Atyr Pharma Inc's revenue growing?

Atyr Pharma Inc (ATYR) revenue declined by 19.1% year-over-year, from $235K to $190K in fiscal year 2025.

Is Atyr Pharma Inc profitable?

No, Atyr Pharma Inc (ATYR) reported a net income of -$74.1M in fiscal year 2025.

What is Atyr Pharma Inc's EBITDA?

Atyr Pharma Inc (ATYR) had EBITDA of -$77.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atyr Pharma Inc's return on equity (ROE)?

Atyr Pharma Inc (ATYR) has a return on equity of -109.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atyr Pharma Inc's free cash flow?

Atyr Pharma Inc (ATYR) recorded an outflow of $62.1M in free cash flow during fiscal year 2025. This represents a 10.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Atyr Pharma Inc's operating cash flow?

Atyr Pharma Inc (ATYR) recorded an outflow of $62.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Atyr Pharma Inc's total assets?

Atyr Pharma Inc (ATYR) had $93.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Atyr Pharma Inc's capital expenditures?

Atyr Pharma Inc (ATYR) invested $77K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Atyr Pharma Inc spend on research and development?

Atyr Pharma Inc (ATYR) invested $60.2M in research and development during fiscal year 2025.

How many shares does Atyr Pharma Inc have outstanding?

Atyr Pharma Inc (ATYR) had 98M shares outstanding as of fiscal year 2025.

What is Atyr Pharma Inc's current ratio?

Atyr Pharma Inc (ATYR) had a current ratio of 5.30 as of fiscal year 2025, which is generally considered healthy.

What is Atyr Pharma Inc's debt-to-equity ratio?

Atyr Pharma Inc (ATYR) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atyr Pharma Inc's return on assets (ROA)?

Atyr Pharma Inc (ATYR) had a return on assets of -79.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Atyr Pharma Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Atyr Pharma Inc (ATYR) held $78.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $62.0M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Atyr Pharma Inc's Altman Z-Score?

Atyr Pharma Inc (ATYR) has an Altman Z-Score of -9.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Atyr Pharma Inc's Piotroski F-Score?

Atyr Pharma Inc (ATYR) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atyr Pharma Inc's earnings high quality?

Atyr Pharma Inc (ATYR) reported a net loss of $74.1M while operations used $62.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.